News Archive of FierceBiotech

ArticleAdded
GlaxoSmithKline wins an FDA nod for its new diabetes drug04-15-14
Angion swings for a $36M IPO as biotech's bear turn drags on04-15-14
Little Lexicon posts positive diabetes data as rival pharma giants race ahead04-15-14
Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy04-15-14
Roche adds a slate of PhIII schizophrenia trial failures to bitopertin's obituary04-15-14
Merck bags FDA approval for its grass pollen pill04-14-14
ThromboGenics is picking between billion-dollar bids, report says04-14-14
NeoStem strikes deal to acquire California Stem Cell04-14-14
BREAKING: Novartis slams the brakes on RNAi development efforts04-14-14
J&J axes a late-stage Botox rival, chopping project staffers04-14-14
J&J teams with Scripps on a new Big Pharma/biotech spinoff matchmaking effort 04-14-14
Cytos hits the self-destruct button as PhIIb asthma study bombs04-14-14
Intercept grabs the spotlight at EASL, builds case for lead drug OCA04-12-14
National Cancer Institute investigating trial outliers to resurrect 'failed' drugs04-11-14
Biotech stocks tumble on phantom terror as analysts struggle to explain04-11-14
Chimerix CEO Moch steps down after compassionate-use controversy04-11-14
AbbVie angles for hep C spotlight as Merck shoulders to the front04-11-14
Impax gives it another go with a once-rejected Parkinson's drug04-11-14
Bayer backs VC fund, FBI calls Russian VCs thieves, Oryzon and Serendex plan IPOs04-11-14
VCs gamble $45M on PhII pain drug, new U.S. base for Spinifex04-09-14
Three IPO hopefuls look to squeeze out $144M as biotech gets bearish04-10-14
Cerulean stumbles with IPO as investors fret over biotech stocks 04-10-14
Biogen's hemophilia hopeful scores a PhIII win as FDA awaits04-10-14
Bristol-Myers jockeys for promising position in hep C drug race04-10-14
Celladon's heart drug grabs 'breakthrough' status at FDA04-10-14
Soon after media storm fades, Chimerix CEO Moch is out the door04-10-14
Watch out Gilead, Merck is mounting a hep C combo comeback04-10-14
FDA drops a hold on Halozyme study04-09-14
'Special K' once again wows investigators in small depression study 04-09-14
Novartis, NEA join $188M gamble on China biotech fund 04-09-14
After burning up $349M, CymaBay aims for Nasdaq as IPOs get shaky04-09-14
GlaxoSmithKline joins a Big Pharma immuno-oncology R&D alliance 04-09-14
Meet Spero, a biotech hopeful with Roche's blessing and a novel antibiotic04-09-14
Low-profile Alios gets a roster of Big Pharma funds to back anti-RSV therapy04-08-14
Lilly preps a PhIII study as breast cancer drug race heats up 04-08-14
TetraLogic bags lymphoma therapy in $13M buyout04-08-14
Versant gambles $12M on Swiss PI3K/mTOR cancer drug upstart 04-08-14
Deerfield eyeing new biotech investments after launching $1.6B fund04-08-14
Alkermes hits PhIII goal line with 'blockbuster' long-acting schizophrenia drug04-08-14
Puma surges as neratinib beats Herceptin in head-to-head breast cancer study04-07-14
Little Deciphera raises its cancer R&D flag in Boston's bustling biotech hub04-07-14
Agios shares spike on enthusiastic response to small, early-stage leukemia study04-07-14
Biotech's breathless quarter of IPOs brings in $2.1B for R&D04-07-14
Roche's pRED jumps into epigenetics with $521M-plus cancer drug deal04-07-14
Sanofi decides to take a second shot on Lemtrada app04-07-14
Pfizer's flagship palbociclib stymies cancer progression, but falls short on survival04-06-14
Memorial Sloan-Kettering hits the brakes on engineered T cell cancer study04-06-14
All eyes on Pfizer as palbociclib prepares to take the stage04-04-14
Merck and Ferring team up on anti-bleeding drug for the developing world04-04-14
AbbVie gets out of the way as the EU prepares for trial transparency04-04-14
Novartis gets new head of Japanese business amid misconduct investigations04-04-14
Amgen's viral cancer vaccine misses its survival goal in melanoma PhIII04-04-14
GTx's CEO finds the door as the company moves on from a PhIII failure04-04-14
Halozyme tanks after another mid-stage setback dings its cancer drug04-04-14
InDex mulls Swedish IPO, Circassia backer posts profit jump, U.K. targets bio investment04-04-14
Sanofi sets sights on Africa with an eye on M&A04-03-14
Pharma giants jostle for the cancer R&D spotlight at AACR04-03-14
Corium pulls off a $52M IPO to fund its needle-free pipeline04-03-14
Celgene pays VCs $47M to up its stake in Acceleron's pipeline 04-03-14
Novartis-backed Neurovance bags $6.3M to focus on ADHD04-03-14
Party drug turned 'miracle' cure for depression spurs hype and stubborn hope 04-03-14
Lumena swings for a $75M IPO to bear down on liver diseases04-03-14
Battered Amarin finally lands a partner for Vascepa04-02-14
Baxter snaps up its hemophilia partner on the verge of a biotech breakup04-02-14
Analysts, experts are dazzled by the blockbuster potential of Novartis' LCZ696 04-02-14
Stallergenes beats Merck to market as FDA OKs its allergy pill04-02-14
GlaxoSmithKline shutters lung cancer vaccine study on latest MAGE-A3 setback04-02-14
FDA panel backs MannKind's inhaled insulin as commercial questions linger04-01-14
Danish trial results show stem cells improve failing hearts04-01-14
Merck KGaA teams up with Pfizer to spotlight new lupus therapies04-01-14
Foresite banks $300M to bet on late-stage biotechs04-01-14
Investors pump $200M into Intarcia's PhIII for once-yearly diabetes therapy04-01-14
Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option 04-01-14
Cubist's superbug drug clears FDA panel, lines up for Pfizer showdown03-31-14
AstraZeneca cozies up to MRC scientists amid an R&D rethink03-31-14
FDA lifts a partial hold on Curis cancer drug03-31-14
Glaxo scraps the ovarian cancer app for Votrient03-31-14
Shares of Prana collapse after long-shot Alzheimer's study flops03-31-14
Tomorrow's cardio blockbusters: Inside 'the next big leap' in controlling cholesterol03-31-14
On the ropes, Novartis' cardiology team declares a blockbuster PhIII knockout 03-31-14
GlaxoSmithKline's darapladib team finds hope in a PhIII bomb 03-30-14
Amgen's PCSK9 drug slashes 'bad' cholesterol in PhIII, stoking blockbuster hopes03-30-14
Biogen wins FDA OK for long-acting hemophilia drug Alprolix03-28-14
AstraZeneca looks to China for kidney disease R&D03-28-14
Ebola still a tough target due to Big Pharma disinterest and few outbreaks03-28-14
MannKind faces stiff skepticism in its third go at FDA approval03-28-14
Merck appoints Baxter exec to fill chief financial officer role03-28-14
Idera spikes as its up-and-down TLR program comes through in PhII03-28-14
Syndax swings for a $69M IPO with 'breakthrough' drug in tow03-28-14
EuroBiotech: Merck KGaA R&D chief exits, Sobi drug flops in PhIII, Adaptimmune gets full-time CEO03-28-14
FDA panel throws dirt on Novartis' would-be cardio blockbuster serelaxin03-27-14
Genmab banks $22M from J&J as myeloma drug ticks forward03-27-14
Pfizer says PCSK9 study was a winner, boosting its chances in hectic R&D race03-27-14
Baxter breaks in two, creating a $6B biopharma business03-27-14
RuiYi banks $15M from A-list backers to amp up Chinese R&D03-27-14
Novartis fuels drive for fast OK of LDK378 with new lung cancer data 03-27-14
GlaxoSmithKline joins a biotech brain trust to make R&D more efficient03-27-14
Exelixis' shares flogged after lead drug disappoints at interim PhIII point03-26-14
Kolltan banks $60M to hit the gas on its cancer drug03-26-14
Fierce readies a new weekly report on the European biotech scene03-26-14
Merck snags rights to NanoBio's adjuvant vaccine tech03-26-14
Sanofi bets big on dengue with eyes on a blockbuster03-26-14
Startup scPharmaceuticals snags $16M for self-dosed injectables03-26-14
With FDA decision looming, GlaxoSmithKline nails European OK for diabetes drug albiglutide03-26-14
Insmed faces another setback as lead therapy flunks PhII lung study03-26-14
Wanna team with AstraZeneca? Post on its website03-25-14
NeuroPhage adds a $17M round to back Alzheimer's drug program03-25-14
Biogen cozies up to MIT with a $5.3M drug discovery pact03-25-14
FDA review slams Novartis's case for beleaguered heart drug serelaxin03-25-14
Merck's new PhIII hep C program may help repair a damaged R&D rep 03-25-14
Seattle startup sets out with $5M, beer molecules and a plan to treat diabetes03-25-14
High-flying biotech stocks take a dive, triggering a bad case of jitters03-25-14
Who's going to win pharma's immunotherapy gold rush?03-24-14
Is the great biotech stock rally kaput?03-24-14
Novartis chairman vows to preserve top R&D budget in retrenchment03-24-14
Gilead scrambles toward hep C cure-all with next-gen combo pill03-24-14
Eyeing rival mAb mob, Novartis touts PhIII secukinumab psoriasis data03-24-14
Celgene wins FDA approval for its blockbuster arthritis contender03-21-14
Boehringer's stumble is InterMune's gain in lung drug race03-21-14
Biogen's Scangos joins Agilent board03-21-14
Versartis grabs $126M in an upsized IPO to fund its orphan drug03-21-14
EU smiles on Lilly and Boehringer's FDA-rejected diabetes drug03-21-14
Novo says Tresiba's down but not out of the blockbuster diabetes race03-21-14
UPDATED: Merck, Endocyte score crucial EMA OK for conditional approval of vintafolide03-21-14
Partnerless Aveo is back on the hunt as Biogen returns a cancer drug03-20-14
Harvard team finger missing protein as a key to Alzheimer's03-20-14
Pfizer snags a 'breakthrough' tag for its meningitis vaccine in a race with Novartis03-20-14
J&J trumpets early success for 3-month Invega Sustenna PhIII schizophrenia trial03-20-14
Biotechs bag $170M in IPO cash as a booming quarter winds down03-20-14
Geron sinks as liver risks plague another imetelstat trial03-20-14
Sanofi launches a vaccine R&D program with blockbuster Prevnar 13 in sights 03-20-14
GlaxoSmithKline's cancer vaccine MAGE-A3 suffers its second PhIII flop03-20-14
McKinsey's four drug launch flavors: Good, bad, ugly and misguided03-19-14
With a $300M buyout fund, Maravai sets out to make a biotech splash03-19-14
The FDA vs the flash mob: Hard questions as parents demand unproven drugs 03-19-14
Novo touts a PhIII hemophilia win as it chases Biogen, Bayer03-19-14
Bristol-Myers partner Alder Bio looking for $115M IPO haul03-19-14
Proteon sets out on its own after Novartis waves off a $550M deal03-19-14
A renal cancer study fails and stock plunges, but Bionomics stays upbeat03-19-14
Biogen hits an FDA speed bump with its next-gen MS drug03-18-14
C3 Jian gets a $60M round from some unconventional investors03-18-14
Upbeat review of failed PhII DMD trial earns Prosensa a big boost to shares 03-18-14
Meet RestorGenex, a biotech mosaic from Celgene founder Barer03-18-14
AstraZeneca signs up for MD Anderson's 'moon-shot' immuno-oncology project 03-18-14
Eager biotechs eye $133M in IPOs as a frenzied quarter closes03-18-14
Report: Novartis circles a deal to buy Gamida Cell in $600M deal03-18-14
Biogen gambles on a $17M Atlas biotech launch, buyout option in hand 03-17-14
Amgen goes 6-for-6 in Phase III, leading the race for a new cardio blockbuster03-17-14
Bristol-Myers inks a $350M deal to pair with Five Prime on immuno-oncology gold rush03-17-14
Informa purges Elsevier unit staff in wake of buyout03-16-14
Intercept scores a PhIII win for lead drug following Friday night frights03-16-14
Chimerix started the week as a punching bag, then pulls off a TKO 03-16-14
Amgen's viral cancer vaccine T-Vec tackles melanoma tumors in PhIII03-15-14
Idenix takes to Europe with its Gilead patent spat03-14-14
Chelsea Therapeutics and the return of pharma's phantom checkbook03-14-14
A who's-that of biotechs snag $119M as the IPO market thunders on03-14-14
Amgen names Piacquad senior VP of business development03-14-14
Is Europe due for a biotech boom all its own?03-14-14
U.K. joins the 'breakthrough' bandwagon with new fast-track program03-14-14
Time, distance and the new world of online business news03-14-14
With $25M in the bank, French startup sets its sights on sepsis03-13-14
Galapagos ships out its CRO biz for $179M to focus on R&D03-13-14
Vectura bags respiratory biotech Activaero for $181M03-13-14
Sage snags $38M from A-list VCs to bankroll its seizure drugs03-13-14
Circassia's record-busting $332M IPO inspires hopes of U.K. renaissance03-13-14
Tesaro pays $17M to team with AnaptysBio on cancer immunotherapies 03-13-14
GlaxoSmithKline maps a route to regulators with positive PhIII asthma data03-12-14
Achaogen grabs $72M from IPO03-12-14
German billionaires back $76M gamble on Glycotope's drug trials03-12-14
AstraZeneca sells off U.K. R&D shop as it packs up for Cambridge03-12-14
Purdue preps potential Zohydro killer for FDA review after positive PhIII 03-12-14
Oxigene roars back to life on positive ovarian cancer study03-12-14
Geron shares blasted as FDA slams the brakes on imetelstat studies03-12-14
Storm-tossed Chimerix rushes into a pilot study, with dying child as its 1st patient 03-12-14
Inside biotech's big year: 2013's approvals, IPOs and sky-high valuations will be tough to top03-11-14
Bayer commits $700M to boost manufacturing for new hemophilia drugs03-11-14
Lumena banks $45M and hits the gas on two liver treatments03-11-14
Novartis's new Basel campus reflects Vasella's (now out-of-fashion) style03-11-14
The dying child vs. the biotech: Everybody loses 03-11-14
Kythera buys back Bayer's stake in PhIII chin-fat therapy in $84M deal03-11-14
La Jolla soars as kidney drug impresses in Phase II, but dosing questions linger03-11-14
Sanofi, UCB team up in $138M deal aimed at tackling biologic blockbusters 03-11-14
Cerulean pitches $75M IPO to give its cancer drug another shot03-10-14
Regado shares pop as drug wins fast-track status03-10-14
J&J, Pharmacyclics and the future of Big Pharma dealmaking03-10-14
J&J partners with a biotech start-up on a new approach to Alzheimer's 03-10-14
Northwest Bio touts a chance to start selling its controversial brain cancer vaccine 03-10-14
Regeneron, Sanofi and Amgen shares suffer on FDA's frets about PCSK9 drug03-07-14
Report: InterMune eyed for a multibillion-dollar buyout03-07-14
AstraZeneca leans toward virtual R&D with a Korean oncology deal03-07-14
Roche's pRED taps Vanderbilt cancer director as new oncology chief03-07-14
Northwest Bio jumps as Phase III trial keeps on rolling03-07-14
GlaxoSmithKline's FDA batting average tops the industry; Lilly, not so much03-07-14
Tiny Recro pulls off a $30M IPO to bankroll its pain drugs03-07-14
NewLink's cancer vaccine brings hopeful investors back down to earth03-07-14
A Phase III win puts Incyte's cancer drug in line for blockbuster status03-07-14
Endo clears the FDA with thrice-spurned drug as 'low-T' controversy boils03-06-14
Tech billionaire Thiel raises $1B for fifth venture fund03-06-14
Obama administration looks to chop back market exclusivity for biologics03-06-14
ZS Pharma bags $55M to take its kidney drug to the FDA03-06-14
Forest's CNS partner Adamas shoots for IPO gold in $69M offering03-06-14
The top 15 cities for biotech venture funding03-06-14
Sangamo's gene editing tech tailors T cells to resist HIV, points to 'cure'03-06-14
Novartis' 'breakthrough' muscle drug is worth $4B, if you ask MorphoSys03-05-14
UPDATED: FDA rejects Eli Lilly's SGLT2 diabetes drug empagliflozin 03-05-14
Merck's latest allergy pill hits the mark in Phase IIb03-05-14
Roche scores upbeat data for a personalized asthma drug with blockbuster hopes03-05-14
Analysts applaud as Bristol-Myers preps a PhIII study for PD-1 cancer combo 03-05-14
Biogen Idec buys into Eisai's BACE camp on Alzheimer's as drug race heats up03-05-14
Xoma drug fails to beat out a placebo in PhII osteoarthritis study03-04-14
Sequencing pioneer Venter raises $70M to launch a biotech to combat aging03-04-14
AbbVie's hep C cocktail aces its latest PhIII study with a sky-high cure rate03-04-14
Theravance bets it can innovate without GlaxoSmithKline as spinoff nears03-04-14
Oxygen Bio shares soar after FDA lifts hold on brain injury drug03-04-14
Roche preps an M&A shopping list as it nears a debt-free future03-04-14
Biotech parties on with billions more raised for R&D work03-04-14
Investigators track 'striking' long-term responses for Bristol-Myers' immunotherapy nivolumab 03-03-14
Gilead CEO Martin joins the exclusive ranks of biotech billionaires03-03-14
India's Lupin queues up for a share of the biosimilar boom03-03-14
Investigators ID a rare antibody that may offer a key to elusive HIV vaccine03-03-14
Scientific insights into brain chemistry trigger drug trials for Down syndrome03-03-14
GlaxoSmithKline hits the brakes on an anti-inflammatory drug from Galapagos03-03-14
Roche racks up another PhIII setback as MetMab flops against lung cancer03-03-14
Actelion's diarrhea drug hops on the FDA fast track02-28-14
Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck antibiotic02-28-14
Novartis' Reinhardt chairmanship officially begins, as Vasella's era fades02-28-14
Celgene nabs an option on Abide and its R&D work on enzyme 'superfamily'02-28-14
Bayer plans to ratchet up its R&D spend and chase down some deals02-28-14
Roche pays millions to U.K. biotech as it doubles down on antibiotics02-28-14
Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months02-28-14
With $375M in the bank, VC Abingworth hunts for a few promising biotechs02-28-14
Longtime R&D critic Valeant finds itself with a growing pipeline, and a setback02-27-14
AstraZeneca unloads an R&D campus after shedding 650 workers02-27-14
Another life sciences IPO pitch in U.K. raises hopes for upturn02-27-14
Analysts cheer on Merck's comeback campaign, pumping up blockbuster forecasts02-27-14
Regeneron's Schleifer hits the $1B mark, but his biotech is just getting started02-27-14
Radius Health looks to catch the IPO wave with $86M pitch02-27-14
Report: Abingworth tees up $330M-plus to bankroll biotech bets02-26-14
REVO looks to expand use of Atryn with preeclampsia PhIII02-26-14
Novartis takes the transparency 'pledge' as Big Pharma critics pounce02-26-14
Anika pops after the FDA finally approves its arthritis jab02-26-14
Novartis to shutter R&D site in June as global reorganization unfolds02-26-14
Northwest Bio shoots for dendritic success where others have failed02-26-14
Mystery U.S. pharma company circles Andromeda and its PhIII diabetes drug02-26-14
FDA OKs AstraZeneca's rare disease drug, but only for a subset of patients02-25-14
Antibiotics player Achaogen sets terms on $65M IPO02-25-14
Merck scuttles a $700M-plus Ariad deal and hands back a once-vaunted cancer drug02-25-14
Lilly hits the mark for comparability to Victoza in head-to-head showdown02-25-14
InterMune scores a big win on PhIII lung drug study02-25-14
Sanofi grabs a discovery pact with gut expert Ardelyx in $198M deal02-25-14
DNAtrix bags $10.8M to advance its cancer-killing virus02-24-14
Corporate VCs back $49M round for dermatology player02-24-14
Assessing the crowd effect on biopharma's risky R&D strategy02-24-14
Bristol-Myers picks up another "breakthrough" trophy in hep C cocktail showdown02-24-14
Busy Servier grabs an option on Celladon's early-stage diabetes work 02-24-14
A struggling ThromboGenics raises the white flag on Jetrea02-24-14
Cinven swoops in to buy control of CRO Medpace for $915M02-24-14
CURx picks up a Gilead cystic fibrosis drug ready for Phase III02-21-14
EU breathes hope into GlaxoSmithKline's latest respiratory contender02-21-14
Isis gears up for Phase III with Biogen-partnered antisense drug02-21-14
Belgian UCB gets ready for CEO change02-21-14
Ariad lets an activist through the gate as shaky buyout rumors linger02-21-14
Incyte's new CEO says his pipeline is underrated--and undervalued02-21-14
Merck KGaA has the firepower to pull off a big buyout, but will it?02-21-14
Merck eyes an FDA nod for its Gardasil heir with billions on the line02-20-14
Investigators: Personalized T cell attack spurs complete remissions of leukemia 02-20-14
Is it news to you? Furiex really is up on the auction block02-20-14
Raptor jumps as its Huntington's hopeful slows the loss of muscle control02-20-14
Report: Father of DMD victim raises $17M for his mission to conquer disease02-20-14
Onconova hammered after top drug rigosertib flunks out a key PhIII study02-20-14
After a Phase II win, Novartis hints at an early app for its skin cancer pill02-19-14
CEO Scangos will see a familiar face become chairman at Biogen Idec02-19-14
AstraZeneca dispatches an advance science team to future HQ campus02-19-14
Lilly heralds a lung cancer victory for blockbuster hopeful ramucirumab02-19-14
Cash-flush Versartis swings for an $80M IPO to advance its orphan drug02-19-14
Industry Voices: FDA expedited approval is vital in filling unmet medical needs02-19-14
Chelsea wins FDA nod for once-spurned Northera, but success isn't guaranteed02-18-14
Akebia swings for a $75M IPO to get its anemia drug into Phase III02-18-14
Novimmune banks $66M for immunotherapies as IPO rumors surface02-18-14
Bayer cites success in hemophilia study, but may still trail Biogen Idec02-18-14
Servier stages an entry into high-stakes CAR-T showdown with Novartis02-18-14
Buzz: Actavis readies $25B Forest Labs buyout in M&A spree02-18-14
Novartis beefs up its cancer immunotherapy pipeline with biotech buyout02-17-14
Japan's RegImmune nails down $9.2M to get its pipeline into the clinic02-14-14
Biotech IPOs: Class of 2014 still rolling as investors line up to cash in02-14-14
Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone02-14-14
GlaxoSmithKline eyes rare disease to widen its respiratory lead02-14-14
AstraZeneca may have a gout blockbuster on its hands with lesinurad02-14-14
Astellas finally bails on Aveo, giving up on the thrice-failed tivozanib02-14-14
The geography of money in biotech02-14-14
Rare-disease powerhouse Alexion grabs an option on muscular dystrophy buyout02-14-14
Isis, Biogen move forward on $300M antisense pact02-13-14
Rare disease deal sends Shkreli's Retrophin soaring02-13-14
Pierre Fabre dives into hot PD-1 field with a biotech tie-up02-13-14
Novartis CEO Jimenez looking for new places to hatchet blockbuster R&D budget 02-13-14
Biotech IPOs roll on with Concert's $84M aria02-13-14
FDA rejects Durect's pitch to market post-operative pain therapy02-13-14
FDA panel pillories The Medicines Co.'s clot-fighting cangrelor02-12-14
AstraZeneca's MedImmune looks to UCSF for some good science and promising ideas02-12-14
AstraZeneca dumps another round of drugs on partner Targacept02-12-14
Ventrus takes a beating, blames placebo effect for PhIII pain failure02-12-14
Biotechs pocket another $115M as the IPO boom thunders on02-12-14
Aggressive Gilead considers head-to-head PAH showdown with Actelion02-12-14
The 23 most influential people in biopharma today02-12-14
Third Rock puts up $45M for a voyage into gene therapy02-12-14
Report: Last year's dealmaking boom will roll on into 201402-11-14
GlaxoSmithKline R&D chief touts the future of 'electroceuticals'02-11-14
FDA gives female libido drug another shot at approval after more studies02-11-14
Market-ready biotechs eye $278M in another busy week for IPOs02-11-14
The world's two Mercks squabble over who gets to be a household name02-11-14
Gilead hands its hep C combo to the FDA as AbbVie race heats up02-10-14
BioDelivery eyes $60M to get its anti-opioid gel through the FDA02-10-14
FDA reviewers paint radically contrasting pictures of The Medicines Co.'s cangrelor02-10-14
Merck takes aim at Sanofi with a Lantus biosimilar of its own02-10-14
Sanofi looks to Regeneron to salvage its R&D rep02-10-14
J&J team marks another setback on depression as mid-stage study flops02-10-14
Antibiotics developer Melinta lands a $70M round for PhIII development blitz02-08-14
Innate goes it alone on a cancer drug, buying out Novo for up to $30M02-07-14
U.S. rep rips the FDA's efforts to speed up drug approvals02-07-14
IPO boom: 8 biotechs bag half a billion in a banner week02-07-14
Questcor hires new CFO02-07-14
Biotech VC Clarus reaches for $375M in its latest fund02-07-14
SAC trader's conviction closes the book on biotech's biggest insider scandal02-07-14
Despite pomp and circumstance, 2014's looking short on blockbusters02-06-14
AbbVie picks Singapore for a $320M production facility02-06-14
Three more biotechs snag $196M in a huge week for IPOs02-06-14
With biotech stocks sizzling, drug developers are bringing home the bacon02-06-14
U.K. biotech Circassia eyes $285M in a London IPO02-06-14
AstraZeneca adds 550 jobs to the chopping block as profits shrivel02-06-14
AstraZeneca quietly sweeps out some notable mid-stage drug programs02-06-14
Norway's BerGenBio banks $12.5M for early-stage cancer drug R&D02-05-14
Purdue launches $12M tit-for-tat fund to seed new biotechs02-05-14
Draper Fisher Jurvetson closes fund with $325M02-05-14
UniQure, Auspex haul in $176M in up-sized IPOs as the biotech boom endures02-05-14
GlaxoSmithKline reloads its pipeline with new PhIII drugs following approvals, setbacks02-05-14
Merck loops Pfizer, Amgen and Incyte in on MK-3475 immunotherapy deal spree02-05-14
FDA rejects IntelGenx and RedHill's migraine film02-04-14
NEA backs $14M round for a biotech startup focused on autism disorder02-04-14
Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success02-04-14
Big Pharma superteam joins NIH to share data, discover new drugs02-04-14
Acucela spots a $162M Japanese IPO to get its eye drug into focus02-04-14
Furiex preps for buyout talks after IBS drug looks promising in PhIII 02-04-14
Edison, Dainippon deepen deal with $50M up front and billions in biobucks02-03-14
Portola takes its 'breakthrough' bleeding drug to PhIII with Bayer, J&J in tow02-03-14
Eager biotechs crowd into Wall Street this week with $500M in IPO pitches02-03-14
Buzz: GlaxoSmithKline prepares to unveil a new PhIII lineup 02-03-14
Pfizer's promising results for palbociclib stir talk of early approval push02-03-14
Merck turns to Ablynx to hunt cancer immunotherapies in potential $2.3B deal02-03-14
Merck turns to Ablynx to hunt cancer immunotherapies in potential $1.7B deal02-03-14
Merck lays off its simian staff as the industry moves away from chimp research01-31-14
Wellcome ponies up $20M to kick-start an Oxford spinoff01-31-14
Matthias Zachert leaves Merck KGaA and the stock drops01-31-14
AbbVie's hep C hopeful aces PhIII and sets off an arms race with Gilead01-31-14
Amgen outpaces its rivals in the race for a PCSK9 blockbuster01-31-14
Two biotech IPOs blast off, spurring dreams--and fears--of an attempted gold rush 01-31-14
Sanofi blocks Eli Lilly's biosimilar of Lantus at the goal line, buys time01-31-14
Aveo's cancer drug circles the drain after a scuttled Phase II trial01-30-14
Despite a years-long dry run, Lilly keeps the faith in its pipeline01-30-14
J&J enlists Yale to oversee clinical trials data sharing 01-30-14
KaloBios calls it quits on its asthma drug after a Phase II flop01-30-14
Progenics tanks after two trial deaths cast doubt on its lead program01-29-14
Wilex cuts 80% of its staff as it pulls the plug on a once-promising cancer therapy01-29-14
Astellas, Medivation's cancer drug Xtandi scores new upbeat PhIII results01-29-14
AstraZeneca is cutting 168 jobs as it shutters an Indian R&D site01-29-14
IPO hopefuls look to extend biotech's window with $123M in fresh pitches01-29-14
Novartis races to the FDA with its 'breakthrough' lung cancer drug01-29-14
Amgen extends PhIII sweep with more promising results for PCSK9 drug01-28-14
Merck's allergy pill sways an FDA panel but faces a long road to success01-28-14
Indian clinical trials plummet 93% as local regs tighten up01-28-14
NIH's Collins vows to tackle science's reproducibility problem01-28-14
The jury's still out on the FDA's 'breakthrough' designation01-28-14
Third Rock backs $14M round for Igenica's cancer-fighting antibodies01-28-14
Pfizer finds its sweet spot on R&D spending, but faces big trouble delivering new drugs01-28-14
AstraZeneca adds a combo research pact to a flurry of new antibiotics deals01-28-14
Merck readies its latest allergy pill for FDA scrutiny and an uphill battle01-27-14
Lilly CEO Lechleiter joins the busy buyside in biotech01-27-14
Tsunami of biotech IPOs will test investors' appetite for R&D01-27-14
Medigene gambles on dendritic cell cancer vaccines in Trianta buyout01-27-14
Is Bristol-Myers fading back in its hot race with Merck for PD-1 lead?01-27-14
A top Pfizer drug flops in two PhIII lung cancer studies01-27-14
Sanofi CEO: Our pipeline is in the top 501-24-14
Teva stands by its MS pill after yet another setback01-24-14
Industry Voices: Inside Genomics--Q&A with Bina CEO Narges Bani Asadi and Dr. Ralph Snyderman01-24-14
Former investment banker tapped as new Shire chairwoman01-24-14
GlaxoSmithKline clears an EU hurdle with its once-delayed GLP-1 diabetes drug01-24-14
PTC slammed after EMA spurns its bid for early OK of DMD drug01-24-14
European regulators hand Novartis a big setback on a top blockbuster prospect01-24-14
Biopharma's middle class spent big in 2013, but price tags are on the rise01-23-14
Can Roche's old R&D campus attract biotechs?01-23-14
Amgen notches another PhIII win for its PCSK9 blockbuster hopeful01-23-14
U.K. group looks to ignite a Boston-style biotech comeback01-23-14
Pfizer's pain med clears PhIII as long-delayed Remoxy waits in the wings01-23-14
J&J carves out a new group to develop drugs for poor countries01-23-14
Buzz: Back from the ER, a wounded Ariad spurs a fresh round of takeover rumors01-23-14
Merck KGaA takes the long view on troubled pharma biz01-22-14
Q4 venture haul pushes 2013 biotech investing past $4.5B01-22-14
Boehringer, Zealand hit reset on GLP-1 diabetes program01-22-14
The dethroned 'King of Biotech' will stay exiled in prison01-22-14
U.K. mulls a 'breakthrough' drug program of its own01-22-14
Yale researchers chide the FDA for failing to enforce high R&D standards01-22-14
Who are the most influential people in biopharma today?01-22-14
BioMarin trades up to $162M for Repligen's stable of HDAC inhibitors01-21-14
Industry giants join MD Anderson's star team for cancer immunotherapies01-21-14
Alzheimer's expert claims he was wooed into biotech insider scandal 01-21-14
Pluristem shines in stem cell trial for muscle injury01-21-14
Amarin tanks as the FDA sticks to its guns on Vascepa01-21-14
Novartis' global reorganization hits home as ax drops on Basel R&D center01-21-14
Post-reform Roche stumbles as top schizophrenia drug fizzles in PhIII01-21-14
FDA panel shakes off J&J's hopes of broader Xarelto use01-17-14
Pulse of J.P. Morgan 2014: Interviews with 17 biopharma execs 01-17-14
Welcome back, Ariad: Iclusig returns after a cold winter01-17-14
ArQule rides high on good news for its never-say-die cancer drug01-17-14
Auspex's $76M IPO pitch tests the limits of biotech's window01-17-14
Prosensa heralds new hope for once-failed muscular dystrophy drug 01-17-14
Novartis oncology chief Hoppenot exits to helm Incyte01-17-14
Shire takes an L on Dermagraft, unloads it to Organogenesis01-17-14
Early gene therapy results tout a promising treatment for blindness01-16-14
Gentium shareholders cry foul on $1B Jazz deal01-16-14
J&J shipping out diagnostics biz for $4.2B01-16-14
Amarin endures another FDA delay as Vascepa languishes01-16-14
Sarepta jumps on fresh optimism for an early approval01-16-14
Merck clears an FDA panel with its clot-fighting vorapaxar01-16-14
Aduro's combo cancer vaccine combo posts positive survival benefits01-15-14
Roche's dealmakers at pRED will continue their global shopping spree in 201401-15-14
Bristol-Myers says it's open to dealmaking in the cancer field01-15-14
Sanofi launches a new antibiotics effort, teams with Fraunhofer01-15-14
Billionaire Soon-Shiong ties a $75M knot with Celgene, vows R&D revolution01-15-14
Chelsea soars after FDA AdCom once again endorses bid to OK Northera01-15-14
For its next trick, Moderna splits in two with $20M cancer venture01-14-14
Concert Pharma tries for a $75M note in IPO01-14-14
Jazz bets up to $397M on Aerial's narcolepsy drug01-14-14
Bristol-Myers looks to rival Gilead for the key to conquering the hep C market01-14-14
Allergan CEO preps multibillion-dollar deal spree to swell pipeline 01-14-14
Regeneron, Bayer reach for the old Eylea magic with combo AMD deal01-14-14
AstraZeneca's Soriot faces off against skeptics, preaches late-stage R&D revival 01-14-14
Amazon's Jeff Bezos bets some of his personal cash on Juno's immunotherapy tech01-14-14
Lilly buys back a migraine therapy from Arteaus Therapeutics01-13-14
Roche picks a new R&D boss as Barron ships out for Google01-13-14
Cell Therapeutics gets a lift as Novartis deals are terminated01-13-14
Merck's fast and furious MK-3475 immunotherapy team guns for a quick approval01-13-14
Cash-laden Moderna snags $125M in Alexion RNA deal01-13-14
GSK dumps a failed muscular dystrophy drug back in Prosensa's lap01-13-14
Sanofi grabs a $700M stake in Alnylam as it ups the ante on RNAi 01-13-14
Merck writes off RNAi, punts Sirna to Alnylam for $175M01-13-14
Teva chooses Erez Vigodman as new CEO01-10-14
Amgen spinoff Atara cranks its Series B up to $52M01-10-14
J&J Innovation settles into a fast-paced global swirl of deal-making01-10-14
Blast at San Francisco Amgen lab injures 201-10-14
Upstart biotech nabs Roche drug, $22.5M A round 01-10-14
It's an industry tradition: Biopharma gets giddy as JPMorgan gets the party started01-10-14
FDA reviewer raises big concerns for Chelsea's attempt at a comeback for Northera 01-10-14
Roche's resurgent pRED makes a U-turn on RNA, strikes deal with Santaris01-10-14
Billionaire backs new program for an Alzheimer's vaccine from AC Immune01-09-14
Zymeworks pockets $15M, woos Lilly with its double-barreled antibodies01-09-14
Pfizer outsources PhIII Bosulif study to upstart Avillion01-09-14
UPDATED: Intercept shares dazzle after early success of PhIIb liver disease drug trial01-09-14
Biogen Idec forges a $320M gene-editing deal aimed at curing inherited blood disorders01-09-14
One of biotech's top R&D chiefs makes the leap to the VC crowd at NEA01-09-14
FDA OKs AstraZeneca's long-delayed diabetes drug dapagliflozin01-08-14
$25M Series B helps Blueprint Medicines pursue individualized cancer therapies01-08-14
Ironwood focuses on sales, sacrifices R&D in restructuring01-08-14
Catalyst boosted as 'breakthrough' PhIII drug clears safety hurdle01-08-14
AbbVie adds a slate of $255M wagers on Seattle Genetics' 'armed' antibody cancer tech 01-08-14
Troubled Teva offers a surprise rival bid for NuPathe01-08-14
J&J Innovation launches a discovery pact with fledgling upstart Scholar Rock01-08-14
AstraZeneca teams with one of the hottest biotechs working on immunotherapies01-08-14
AstraZeneca adds a second cancer R&D deal to its pact with Horizon Discovery01-07-14
Epizyme shares rocket up on news of $29M milestone awards01-07-14
In search for success, R&D teams are overcrowding small drug franchises01-07-14
Texas' Bellicum gets $15M to expand work on gene 'switch' tech01-07-14
Neurocrine shares soar with a promising second take on a PhIIb drug01-07-14
Lilly is carving up to a billion dollars out of its struggling R&D division01-07-14
Top cancer research institutions split $540M windfall01-06-14
Fast-growing Aratana beefs up pet drug pipeline with a $44M buyout 01-06-14
Analysts score the winners in the FDA's new 'breakthrough' category 01-06-14
Powerhouse biotech startup charges into legal wrangle over pioneering immunotherapy01-06-14
GE beefs up life sciences division with $1.06B Thermo Fisher deal01-06-14
J&J gambles $12.5M in rare Big Pharma bet on a stem cell therapy01-06-14
An ominous trend resurfaces as new drug approvals plunge in 201301-06-14
Google Ventures backs DNAnexus's $15M round for R&D cloud platform 01-03-14
AstraZeneca buys a CDK9 cancer drug portfolio01-03-14
Buzz: If it's an Irish biopharma company, it's on analysts' M&A list01-03-14
NeXeption raises $21.5M to launch dermatology startup Alexar01-03-14
Genetics startup Agilis names industry vet Zorich CEO01-03-14
A step ahead of controversial transparency rules, Sanofi commits to open access01-03-14
Ambitious HDL program joins a growing list of high-profile clinical failures01-03-14
Buzz: A buyer is in talks to acquire a big stake in Celltrion01-02-14
U.S. domination of global biomedical R&D slips as Asian budgets swell 01-02-14
NVCA starts 2014 with a hopeful wrap-up on the biotech IPO party 01-02-14
Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe01-02-14
FDA lifts a partial hold on Cell Therapeutics' leukemia drug01-02-14
Revance, Dicerna ring out an IPO boom year with $155M in pitches01-02-14
Argos swings for a $60M IPO in the shadow of Dendreon's struggles12-31-13
Third Rock's Eleven pitches a $69M IPO to fuel its PhIII dry eye program12-31-13
Karolinska's Axelar comes up short in Phase II with lung cancer drug12-30-13
UPDATED: FDA spurns Sanofi's MS drug Lemtrada on fatally flawed PhIII design 12-30-13
The 5 biggest trends in biopharma R&D in 201312-20-13
FDA puts off decision on Amarin's fish oil pill, but investors keep the faith12-20-13
GlycoMimetics gets back on the IPO train with another pitch12-20-13
Jazz Pharma trades $1B for Gentium and a well-traveled orphan drug12-20-13